LHLiesbeth Hoekman

Liesbeth Hoekman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liesbeth Hoekman has a total of 324 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global and specific mechanisms stimulate mistranslation in cancer

    by Demi Wernaart, Amos Fumagalli, Mrittika Adhikary, Xiaodong Feng, Olaf Geintzer, Edwin S. Kyei-Baffour, Onno B. Bleijerveld, Liesbeth Hoekman, Ceri Zwart, Alexander Fish, et al.

    Tryptophan codon-specific mistranslation, in the form of ribosomal frameshifting and tryptophan-to-phenylalanine (W > F) codon reassignments (substitutants), is induced in cancer cells by the limiting level of tryptophan imposed by anti-tumour immunity. While the oncogenic mitogen-activated protein kinase pathway drives frameshifting, whether substitutants are genetically regulated remains unknown. Here we screened for genes that control W > F substitutants following interferon-γ-mediated tryptophan shortage. This screen identified ADAR1, an enzyme that converts adenosine to inosine in double-stranded RNA molecules, and FTSJ1, an enzyme that 2′-O-methylates the anticodon region of several tRNAs. We demonstrate that ADAR1 sustains expression of key players in the ribosome quality control pathway, which in turn is essential for mistranslation events. FTSJ1, in contrast, specifically drives W > F mistranslation by methylation of tRNATrp to promote its binding to WARS1 loaded with phenylalanine instead of tryptophan. As ADAR1 and FTSJ1 levels are elevated in many cancer types, we propose that cancer cells deploy global and specific mechanisms to promote mistranslation in response to anti-tumour immunity.

  • A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator

    by Anniek Zaalberg, Audrey Lacoste, Emma Minnee, Isabel Mayayo-Peralta, Karianne Schuurman, Sebastian Gregoricchio, Thijs A. van Schaik, Liesbeth Hoekman, Dapei Li, Eva Corey, et al.

  • Open Access

    Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production

    by Remco Nagel, Adva Kochavi, Karine Flem-Karlsen, Mrittika Adhikary, Yali Gal-On, Maria G. Klaoudatou, Julien Champagne, Lorenzo Valcanover, Heyilimu Palashati, Morten M. Nielsen, et al.

    Arginine biosynthesis is frequently suppressed in cancer because of the loss of argininosuccinate synthase 1 (ASS1) expression, rendering cancer cells reliant on extracellular arginine. This feature has driven the development of systemic arginine-depleting strategies, which are clinically safe but offer limited clinical benefit. In this study, we demonstrated that under arginine scarcity, cancer cells with low ASS1 expression resort to aberrant mRNA translation, characterized by ribosomal frameshifts and amino acid misincorporations. Although aberrant proteins originated from most arginine codons, the predominant effect was observed at AGA. This codon preference was caused by a selective decrease in tRNAArg (UCU) levels following arginine deprivation, linked to methyltransferase-like 1 (METTL1)–mediated tRNA modification. Proteomics and immunopeptidomics analyses validated that arginine shortage induced aberrant protein production at the endogenous level. T-cell receptor (TCR) T cells that specifically recognize these HLA-presented mistranslated peptides efficiently killed cancer cells after arginine deprivation. These results lay the foundation for improved cancer therapies by combining systemic arginine-depleting strategies with TCR-based targeting of nonclassical neoantigens. Significance: Aberrant protein production induced by arginine deprivation in ASS1-low cancers leads to production of neoantigens that represent promising targets for TCR-T cell therapies.


  • Open Access

    DOT1L Shapes ncPRC1-Target Gene Repression to Maintain Germinal Center B Cell Identity of Diffuse Large B cell Lymphoma

    by Camiel Göbel, Rachele Niccolai, Sebastian Gregoricchio, Marnix Hugo Philip de Groot, Stijn F.K. Kneefel, Maaike Kreft, Hendrik J. Kuiken, Cor Lieftink, Nils Eickhoff, Liesbeth Hoekman, et al.

    Germinal center (GC) B cell-like diffuse large B cell lymphoma (GCB-DLBCL) depends on the cooperative activity of the histone methyltransferases DOT1L and EZH2 to maintain its pro-proliferative GCB cell identity while repressing plasma cell (PC) differentiation. To explore the mechanisms underlying the co-dependency between DOT1L and EZH2 in GCB-DLBCL, we performed an EZH2 inhibition (EZH2i)-anchored genome-wide CRISPR interference screen and identified multiple candidate genes encoding components of non-canonical (nc) PRC1 complexes, including USP7, KDM2B, RING1, and PCGF1. We identified USP7 as potential direct target of DOT1L, whose downregulation was associated with increased EZH2i sensitivity in multiple GCB-DLBCL cell lines. Furthermore, we observed that DOT1L influences the composition of chromatin-bound ncPRC1 complexes and regulates, in part, the deposition of H2AK119 monoubiquitination (H2AK119ub1) at gene promoters co-occupied by H3K27me3, here defined as PRC1/2 targets. These PRC1/2 targets were specifically enriched in PC signature genes, whose derepression was associated with DOT1L inhibition (DOT1Li)-mediated loss of H2AK119ub1. This study reveals novel insights into the role of DOT1L and its functional co-dependence with EZH2 in maintaining GCB identity in DLBCL, supporting a model in which concurrent reduction of H2AK119ub1 and H3K27me3 promotes differentiation toward an anti-proliferative, plasma cell-like state.

  • Open Access

    DEprot : a comprehensive R-package for the analysis of label-free quantitation mass spectrometry data

    by Nils Eickhoff, Liesbeth Hoekman, Onno Bleijerveld, Andries M Bergman, Wilbert Zwart, Sebastian Gregoricchio

    In recent years, studies investigating protein–protein interactions on a proteome-wide scale have increased exponentially. These developments were achieved through implementation of new techniques, as well as improvements in mass spectrometry hardware. However, issues specific to this type of technique, such as distinct imputation of random and not-at-random missing proteins, have not been completely addressed. Here, we present DEprot, an R-package providing a comprehensive toolset for end-to-end analysis and visualization of proteomics data. Moreover, we implemented a serial imputation strategy for handling non-random missing values, particularly suitable for protein enrichment techniques and knockout conditions.

  • Open Access

    Histone methyltransferase DOT1L maintains cell state and restricts cytotoxic potential of CD8 T cells

    by Muddassir Malik, Willem-Jan de Leeuw, Muhammad Assad Aslam, Eliza Mari Kwesi-Maliepaard, Teun van Den Brand, Bram van Den Broek, Maxime Kempers, Liesbeth Hoekman, Natalie Proost, Tibor van Welsem, et al.

    The histone methyltransferase DOT1L is emerging as a central epigenetic regulator in immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of memory characteristics but has also been reported to compromise CD8 T cell viability and antitumor reactivity. Here, we determined the cell-intrinsic role of DOT1L in mature mouse CD8 T cells. After conditional deletion of Dot1L in vitro, CD8 T cells retained in vivo proliferative capacity and antitumor reactivity. Moreover, Dot1L knockout CD8 T cells showed increased antigen-specific cytotoxicity toward tumor cells in vitro. Mechanistically, loss of DOT1L resulted in an altered cell state with loss of T cell and gain of innate-like features. These transcriptional changes were mediated by loss of DOT1L methyltransferase activity in a dose-dependent manner. Our findings show that in mature CD8 T cells, ablation of DOT1L activity is well tolerated and reprograms them to gain innate-like memory cell characteristics and enhance intrinsic cytotoxic capacity.


  • NASP modulates histone turnover to drive PARP inhibitor resistance

    by Sarah C. Moser, Anna Khalizieva, Josef Roehsner, Elisabeth Pottendorfer, Milo L. Kaptein, Giulia Ricci, Vivek Bhardwaj, Onno B. Bleijerveld, Liesbeth Hoekman, Ingrid van der Heijden, et al.

    The poly(ADP-ribose) polymerase inhibitor (PARPi) class of drugs represents a remarkable advance in the treatment of patients with homologous recombination-deficient tumours, but resistance remains a challenge1-5. Although most research has focused on the downstream consequences of PARPi exposure to tackle resistance, the immediate effect of PARP inhibition on the chromatin environment and its contribution to PARPi toxicity remains elusive. Here we show that PARP inhibition induces histone release from the chromatin. This presents a vulnerability of PARPi-resistant cancer cells, which require histone homeostasis mechanisms to sustain elevated DNA replication rates and survival. Through functional genetic screens, we identified NASP as a key factor in maintaining the stability of evicted histones via its TPR motifs. Loss of NASP renders tumour cells hypersensitive to PARPi treatment in vitro and in vivo, impairs replication fork progression and elevates levels of replication-associated DNA damage. Moreover, NASP acts together with the INO80 complex and the chaperoning activity of PARP1 to ensure efficient histone turnover and prevent the accumulation of lethal DNA damage. Collectively, our work reports on histone eviction as an immediate cellular response to PARPi treatment and provides a promising avenue for targeting histone supply pathways to overcome PARPi resistance.


  • Open Access

    Loss of ribosomal protein uL14 enables tumor escape from T cell immunosurveillance

    by Anna Dopler, Edwin S Kyei-Baffour, Mandy Kerkhoff, Ferhat Alkan, Yuval Malka, Kelly Hoefakker, Rob van der Kammen, Liesbeth Hoekman, Onno Bleijerveld, Antonia Bradaric, et al.

    The presentation of peptides on HLA molecules is essential to CD8+ T cell responses. Here, we show that loss of uL14 significantly downregulates the expression of antigen processing and presentation (APP) components in melanoma cell lines. Peptides generated following knockdown show different characteristics, with altered peptide charge, and differences in anchor residue positions. These peptides also have lower predicted binding to the HLA alleles and a shorter predicted HLA-peptide complex half-life. These result in a functional difference in APP, and knockdown of uL14 causes a reduction in the ability of CD8+ T cells to recognize and kill melanoma cells in a co-culture assay. Together, our data suggest that loss of uL14 alters the peptide pool available for presentation and thus may act as an escape mechanism from tumor immune surveillance.

  • Open Access

    TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination

    by Nils Eickhoff, Janina Janetzko, Nuno Padrão, Sebastian Gregoricchio, Joseph C. Siefert, Liesbeth Hoekman, Simon Linder, Onno Bleijerveld, Andries M. Bergman, Wilbert Zwart

    The Androgen Receptor (AR) is a ligand-dependent transcription factor that drives prostate cancer development and progression. Although, a detailed effect on AR biology has been described for a number of interacting proteins, many AR coregulators remain to be characterized in relation to their distinct impact on AR function. Here, we describe TRIM33 as a conserved AR-interactor across multiple prostate cancer cell lines. We observed that TRIM33 and AR share overall chromatin interaction profiles, in which TRIM33 is involved in downstream responsive transcriptomic output. In contrast to prior reports, we show that TRIM33 does not impact AR protein stability, but instead propose a model in which TRIM33 facilitates maximal AR activity by interfering with H2BK120 ubiquitination levels.


  • Open Access

    Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma

    by Camiel Göbel, Rachele Niccolai, Marnix H. P. de Groot, Jayashree Jayachandran, Joleen Traets, Daan J. Kloosterman, Sebastian Gregoricchio, Ben Morris, Maaike Kreft, Ji-Ying Song, et al.

    Differentiation of antigen-activated B cells into proproliferative germinal center (GC) B cells depends on the activity of the transcription factors myelocytoma (MYC) and B-cell lymphoma 6 (BCL6), and the epigenetic writers disruptor of telomeric silencing 1-like (DOT1L) and enhancer of zeste homolog 2 (EZH2). GCB-like diffuse large B-cell lymphomas (GCB-DLBCLs) arise from GCB cells and closely resemble their cell of origin. Given the dependency of GCB cells on DOT1L and EZH2, we investigated the role of these epigenetic regulators in GCB-DLBCLs and observed that GCB-DLBCLs synergistically depend on the combined activity of DOT1L and EZH2. Mechanistically, inhibiting both enzymes led to enhanced derepression of polycomb repressive complex 2 target genes compared with EZH2 single treatment, along with the upregulation of BCL6 target genes and suppression of MYC target genes. The sum of all these alterations results in a “cell identity crisis,” wherein GCB-DLBCLs lose their proproliferative GC identity and partially undergo plasma cell differentiation, a state associated with poor survival. In support of this model, combined epidrugging of DOT1L and EZH2 prohibited the outgrowth of human GCB-DLBCL xenografts in vivo. We conclude that the malignant behavior of GCB-DLBCLs strongly depends on DOT1L and EZH2 and that combined targeting of both epigenetic writers may provide an alternative differentiation-based treatment modality for GCB-DLBCL.